"Why partner with us? Because we take care of your product as if it were our own. We manage the regulatory and reimbursement complexities to ensure our partners’ drugs are commercialised to the highest standards. Our track record speaks for itself." - Carlo Montagner, CEO

Specialised Therapeutics Asia (STA) is an international biopharmaceutical company which has rapidly grown to become the largest independent specialist pharmaceutical company in Australia, New Zealand and SE Asia. Headquartered in Singapore, we have regional offices in Melbourne and Auckland.

We collaborate with international partner companies, championing their speciality products from pre-registration through to full commercialisation. Our BD team is actively seeking and evaluating in-licensing opportunities for products in clinical development or market ready.

Our Current Partners



"We are open to joint ventures, typical royalty and milestone-based licensing agreements or other creative, mutually beneficial, partnering opportunities."

Each partnership is unique in its deal structure. As an independent company we are not encumbered by complex approval processes, enabling thorough and fast due diligence and timely proposal of terms. Our independence allows us to move quickly through due diligence and we can propose terms within weeks.

Dr Anant Murthy from Takeda discusses partnering with STA

"Our partners have often been surprised how little time and resources are required of them, throughout the regulatory and reimbursement submission processes."

Every team member at STA has extensive industry experience having worked in large international biopharmaceutical companies across the region. Once a deal is done, our team is able to efficiently navigate complex regulatory and reimbursement pathways in our key regions of Australia, New Zealand and across South East Asia for timely and successful outcomes. Our expertise in sales and marketing has resulted in rapid market uptake and sales growth with excellent outcomes shared by both partners.
Our existing portfolio includes oncology, haematology, neurosurgery, supportive care, ophthalmology and genomic assays. Furthermore, we have demonstrated capability to rapidly expand into additional therapeutic areas.

For a list of partnering announcements, please click here.

To contact our Business Development team, please email:


New Drug for Gastrointestinal Stromal Tumours (GIST) to be L

A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be ...


Specialised Therapeutics Signs Exclusive Deal for New Haemat

STA secures exclusive AU and NZ commercialisation rights for Rigosertib, a promi...


Collaborate: We work closely with global business partners

And we take care of their products as if they were our own. We also manage compl...


10 Years of Partnering

ST's success has been built on a strategy of partnering with international biote...


From Big Pharma to Small Starts: Risking it All on a Life-Sa

March, 2016: Our story as featured in The Australian newspaper on 19 March, 2016...


CEO Carlo Montagner Discusses Recent Partnership Deal

CEO Carlo Montagner’s Latest Blog...